NCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
Clinical Trials
7 trialsNCT07361705 2026-01-23
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1 Not yet recruiting
NCT07329322 2026-01-09
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 2 Not yet recruiting
NCT07285148 2025-12-16
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2 Not yet recruiting
NCT07256509 2025-12-05
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2 Not yet recruiting
NCT06908772 2025-04-03
Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT06380348 2024-04-23
JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting